| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FCA.11.1 |
| P698 | PubMed publication ID | 21453031 |
| P2093 | author name string | Alexander M Seifalian | |
| Alamgir M N Kabir | |||
| Amalan Selvarajah | |||
| P2860 | cites work | A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization | Q28202763 |
| Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery | Q28206536 | ||
| What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis | Q28210332 | ||
| Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial | Q28210537 | ||
| TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions | Q28222747 | ||
| Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial | Q28251137 | ||
| Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern | Q28291903 | ||
| Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study | Q31102731 | ||
| Stromal cell-derived factor-1 enhances pro-angiogenic effect of granulocyte-colony stimulating factor | Q33270596 | ||
| Real-world safety and efficacy of the endeavor zotarolimus-eluting stent: early data from the E-Five Registry | Q33303311 | ||
| Clinical pharmacokinetics of everolimus | Q33358752 | ||
| Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry | Q33389674 | ||
| Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications | Q34576422 | ||
| Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells | Q34719651 | ||
| Paclitaxel (taxol) | Q34723890 | ||
| Rapamycin inhibits vascular smooth muscle cell migration | Q34736691 | ||
| Advances in vascular tissue engineering | Q35542593 | ||
| Endothelial progenitor cells: characterization and role in vascular biology | Q35867837 | ||
| Mobilizing endothelial progenitor cells | Q36012003 | ||
| Drug eluting stents: an updated meta-analysis of randomised controlled trials | Q36282710 | ||
| Hepatocyte growth factor induces angiogenesis in injured lungs through mobilizing endothelial progenitor cells. | Q47917252 | ||
| Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. | Q50176817 | ||
| Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials. | Q50922855 | ||
| Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. | Q50999650 | ||
| Enhanced intimal thickening of expanded polytetrafluoroethylene grafts coated with fibrin or fibrin-releasing vascular endothelial growth factor in the pig carotid artery interposition model. | Q51015846 | ||
| In vivo vasculogenic potential of human blood-derived endothelial progenitor cells. | Q51059546 | ||
| Human endothelial progenitor cell attachment to polysaccharide-based hydrogels: a pre-requisite for vascular tissue engineering. | Q51061158 | ||
| Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. | Q51066198 | ||
| Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. | Q51066201 | ||
| In vivo h-VEGF165 gene transfer improves early endothelialisation and patency in synthetic vascular grafts. | Q51087695 | ||
| Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. | Q51093369 | ||
| Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry. | Q51102527 | ||
| Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. | Q51133146 | ||
| Sirolimus-eluting versus uncoated stents in acute myocardial infarction. | Q51133149 | ||
| Incorporation of a lauric acid-conjugated GRGDS peptide directly into the matrix of a poly(carbonate-urea)urethane polymer for use in cardiovascular bypass graft applications. | Q51167273 | ||
| Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. | Q51170005 | ||
| Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. | Q51174714 | ||
| Dual role of VEGF in pretreated experimental ePTFE arterial grafts. | Q51451283 | ||
| Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. | Q51472391 | ||
| Efficacy of n-3 polyunsaturated fatty acids according to clinical characteristics of patients with recent myocardial infarction: insights from the GISSI-Prevenzione trial | Q57628867 | ||
| Long-term clinical outcome with titanium-nitride-oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population | Q57914634 | ||
| Two-year follow-up after percutaneous coronary intervention with titanium-nitride-oxide-coated stents versus paclitaxel-eluting stents in acute myocardial infarction | Q57914679 | ||
| Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. | Q36847551 | ||
| Thrombosis and drug-eluting stents: an objective appraisal | Q36872486 | ||
| Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis | Q36942534 | ||
| A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease | Q36954861 | ||
| Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients | Q36976769 | ||
| Progenitor cells and vascular disease | Q37053167 | ||
| Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis | Q37197672 | ||
| Coronary stents: looking forward | Q37783396 | ||
| Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. | Q38392662 | ||
| Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial | Q38408984 | ||
| Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry | Q39986890 | ||
| Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). | Q40300202 | ||
| Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials | Q40319620 | ||
| Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). | Q40458505 | ||
| Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised cl | Q40525372 | ||
| Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design | Q42484185 | ||
| Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). | Q42781666 | ||
| Comparison of zotarolimus-eluting and everolimus-eluting coronary stents | Q43016712 | ||
| Duration of dual antiplatelet therapy after implantation of drug-eluting stents. | Q43128835 | ||
| Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization | Q43741707 | ||
| Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events | Q43791681 | ||
| Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry--STENT Group | Q43902530 | ||
| An assessment of covalent grafting of RGD peptides to the surface of a compliant poly(carbonate-urea)urethane vascular conduit versus conventional biological coatings: its role in enhancing cellular retention | Q44118806 | ||
| 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry). | Q44192454 | ||
| Surface functionalization and grafting of heparin and/or RGD by an aqueous-based process to a poly(carbonate-urea)urethane cardiovascular graft for cellular engineering applications | Q44549267 | ||
| Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). | Q44612612 | ||
| The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). | Q44803691 | ||
| Drug-eluting or bare-metal stents for acute myocardial infarction | Q44836234 | ||
| Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells | Q45147173 | ||
| Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial | Q45220082 | ||
| A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial | Q45226114 | ||
| Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the Xience V Everolimus-Eluting Coronary Stent | Q45254875 | ||
| Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial | Q45287552 | ||
| Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials | Q45851333 | ||
| Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial | Q46214432 | ||
| Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation | Q46377882 | ||
| Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial | Q46395870 | ||
| Endothelial cell recovery between comparator polymer-based drug-eluting stents | Q46464108 | ||
| Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry | Q46489660 | ||
| First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial | Q46533338 | ||
| Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials | Q46655103 | ||
| Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study | Q46763176 | ||
| Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications. | Q46883924 | ||
| Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks | Q46921263 | ||
| Nanocomposite containing bioactive peptides promote endothelialisation by circulating progenitor cells: an in vitro evaluation | Q46934819 | ||
| Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study | Q46939621 | ||
| Clinical and angiographic follow-up of small vessel lesions treated with paclitaxel-eluting stents (from the TRUE Registry). | Q47289365 | ||
| Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials | Q47908774 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 251-270 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Future Cardiology | Q15765184 |
| P1476 | title | How safe and how good are drug-eluting stents? | |
| P478 | volume | 7 |
| Q37283669 | Deformationally dependent fluid transport properties of porcine coronary arteries based on location in the coronary vasculature |
| Q48123455 | In Vitro Quantification of Luminal Denudation After Crimping and Balloon Dilatation of Endothelialized Covered Stents. |
| Q38034502 | Magnetically targeted delivery of therapeutic agents to injured blood vessels for prevention of in-stent restenosis. |
| Q39012152 | Nanofiber-coated drug eluting stent for the stabilization of mast cells |
| Q37887771 | Nitric oxide: a guardian for vascular grafts? |
| Q41634009 | Surface modification of endovascular stents with rosuvastatin and heparin-loaded biodegradable nanofibers by electrospinning |
Search more.